Study Procedures
PULMONARY EMBOLISM
Selection of the bariatric procedures was independent of this study. Standard postoperative thromboprophylaxis and nutrition management are described in eMethods 2 in Enrolled patients received an oral dose of 10 mg of rivaroxaban (Xarelto, Bayer Pharma AG) under nonfasting conditions on the first postoperative day. Rivaroxaban, 10 mg/d, was selected based on our 2 previous phase 1 pharmacokinetic/pharmacodynamic trials and the in vitro thrombin generation study.Pulmonary embolism was assessed based on clinical signs and symptoms during hospitalization and during the follow-up visits. Suspected PE was confirmed by contrast-enhanced spiral computed tomography or ventilation/perfusion scintigraphy.